Sean T. O'Leary, MD, MPH, outlines 2026-2027 AAP influenza, COVID-19, and RSV guidance.
News|Videos|March 30, 2026
Q1 2026 recap: Top videos in pediatric care
Author(s)Celeste Krewson, Assistant Editor
Fact checked by: Yasmeen Qahwash
As we step into Q2 2026, take a look back at our top video interviews and packages of Q1.
Advertisement
Advertisement
Throughout the first quarter of 2026, our coverage at Contemporary Pediatrics has highlighted a broad spectrum of critical updates and emerging research across diverse therapeutic areas. Key focal points include evaluating demographic disparities in oral food challenge completion rates, assessing the safety and efficacy profile of tapinarof cream in pediatric atopic dermatitis, and examining the clinical implications of the newly updated US Dietary Guidelines.
Related to this article
DBV filed a BLA for the Viaskin peanut patch in peanut-allergic children aged 4-7, citing phase 3 VITESSE data, and requested priority review.
Brian Vickery, MD, discusses a phase 1 trial evaluating the safety and tolerability of a microneedle stamp designed to deliver peanut protein through the skin.
Glucommander Pediatrics received FDA Breakthrough Device Designation for IV insulin dosing in hospitalized children younger than 2 years, but remains uncleared.
ISPAD, EASD, and ADA urge pediatric diabetes teams to build center-specific transition policies, use readiness checklists, and ensure timely handoffs to adult clinicians.
Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.
This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
In national emergency department data from 2005 to 2024, fractures were the most common pediatric e-bike injury, and e-bikes had the second-highest admission rate.
Advertisement
Advertisement